1 **Type of manuscript**: Original article

- 2
- 3 Title: Rapid diagnosis of SARS-CoV-2 infection by detecting IgG and IgM antibodies
- 4 with an immunochromatographic device: a prospective single-center study
- 5
- 6 **Running title**: Rapid serologic test to diagnose SARS-CoV-2 infection
- 7
- 8 **Authors**: Felipe Pérez-García 1, ¥,*, Ramón Pérez-Tanoira 1, ¥, Juan Romanyk 1,2,
- 9 Teresa Arroyo 1, Peña Gómez-Herruz 1, Juan Cuadros-González 1,2
- 10
- 11 (*), Correspondence: <u>felipe.perez.garcia.87@gmail.com</u> (FPG)
- 12 (¥), Both authors contributed equally to this study.
- 13

14 **Authors affiliations**:

- 15 (1), Departamento de Microbiología Clínica, Hospital Universitario Príncipe de Asturias,
- 16 Madrid, Spain.
- 17 (2), Departamento de Biomedicina y Biotecnología, Facultad de Medicina, Universidad
- 18 de Alcalá de Henares, Spain.
- 19

20 <u>C</u>	orrespondence	author: Felipe	Pérez-García;	Hospital	Universitario	Príncipe de
-------------	---------------	----------------	---------------	----------	---------------	-------------

- 21 Asturias. Servicio de Microbiología Clínica. Carretera de Alcalá, s/n, 28805 Meco
- 22 (Madrid); Telf.: + 34 91 87 81 00; e-mail: felipe.perez.garcia.87@gmail.com

23

- 24 <u>Alternative correspondence author</u>: Ramón Pérez-Tanoira; Hospital Universitario
- 25 Príncipe de Asturias. Servicio de Microbiología Clínica. Carretera de Alcalá, s/n, 28805
- 26 Meco (Madrid); Telf.: + 34 91 87 81 00; e-mail: ramontanoira@hotmail.com

28

29 Abstract

30 **Objectives:**

SARS-CoV-2 infection diagnosis is challenging in patients from 2-3 weeks after the onset of symptoms, due to the low positivity rate of the PCR. Serologic tests could be complementary to PCR in these situations. The aim of our study was to analyze the diagnostic performance of one serologic rapid test in COVID-19 patients.

35 Methods:

We evaluated an immunochromatographic test (*AllTest COVID-19 IgG / IgM*) which detects IgG and IgM antibodies. We validated the serologic test using serum samples from 45 negative patients (group 1) and 55 patients with COVID-19 confirmed by PCR (group 2). Then, we prospectively evaluated the test in 63 patients with clinical diagnosis of pneumonia of unknown etiology that were COVID-19 negative by PCR (group 3).

42 **Results:**

All 45 patients from group 1 were negative for the serologic test (specificity = 100%). Regarding group 2 (PCR-positive), the median time from their symptom onset until testing was 11 days. For these 55 group-2 patients, the test was positive for either IgM or IgG in 26 (overall sensitivity = 47%), and in patients tested 14 days or more after the onset of symptoms, the sensitivity was 74%. Regarding the 63 group-3 patients, median time after symptom onset was 17 days, and the test was positive in 56 (89% positivity).

50 **Conclusions:** Our study shows that serologic rapid tests could be used as a 51 complement of PCR to diagnose SARS-CoV-2 infection after 14 days from the onset of 52 symptoms and in patients with pneumonia and negative PCR for SARS-CoV-2.

53

54 Keywords:

- 55 SARS-CoV-2; COVID-19; inmunocromatography; serologic rapid test; pneumonia;
- 56 diagnosis
- 57

58 Introduction

59 The pandemic due to SARS-CoV-2 that started in Wuhan four months ago (1,2) has 60 caused until April 8, 2020, a total of 1,353,361 cases and 79,235 deaths worldwide (3). Spain is the country of the European region that has been most affected by the 61 62 infection, accounting for 140,510 cases and 13,798 deaths by April 8 (3). From the 63 beginning of the pandemic, one of the main concerns was the complexity and excessive time to results of the diagnostic test, based on polymerase chain reaction 64 65 (PCR) (4,5). Few clinical microbiology laboratories were prepared at this time to 66 process such a massive volume of samples that grew exponentially. In our hospital, which is a medium-sized center (490 beds), from March 5 to April 6, a total of 7,453 67 respiratory samples (the vast majority nasopharyngeal exudates) were processed for 68 69 SARS-CoV-2 PCR, reaching a positivity rate between 20 and 40%. Another problem was the low positivity rate of nasopharyngeal samples in patients presenting a clinical 70 syndrome compatible with COVID-19 in the second and third week of infection (1,6-8), 71 72 which is generally the period in which patients are admitted to the hospital (1). Besides, 73 most patients presented a non-productive cough (9), and this fact, together with the 74 high risk of generating aerosols in bronchoscopies explains that most respiratory 75 samples came from the upper respiratory tract, where the virus concentration is lower beyond the first week after the onset of symptoms (8,10). As a consequence, the 76 77 positivity rate of the PCR in these patients could be lower than expected and many of 78 them were hospitalized with a provisional diagnosis of pneumonia of unknown etiology 79 and possible COVID-19.

80

These limitations have led to development of different microplate ELISA tests (11,12). Recently published studies confirm the usefulness of combining PCR in nasopharyngeal exudates with the detection of IgM and IgG antibodies in the blood (13). The combination of molecular and serologic techniques allowed some authors to

achieve a sensitivity of 97% for diagnosis of SARS-CoV-2 infection (12). However, those time-consuming tests based on ELISA are not as suitable for clinical use as rapid tests and, as a matter of fact, cannot be included in the management algorithms in emergency departments (12-15).

89 Since the beginning of the epidemic in Spain, information emerged about the 90 availability of rapid serological diagnostic kits that detected IgG and IgM antibodies 91 using immunochromatographic (ICT) tests. However, there are very few published 92 studies about the clinical application of these kits (15). Our aim was to evaluate the 93 diagnostic performance of one of these serologic rapid tests, first by a validation of the test in negative control patients and confirmed cases of COVID-19, and then by a 94 prospective evaluation in patients with pneumonia of unknown etiology and a clinical 95 diagnosis of COVID-19 with negative PCR for SARS-CoV-2. 96

97

98 <u>Methods</u>

99 **Population and study period**:

100 We included three groups of patients in our study:

101 <u>Group 1 (healthy controls)</u>: a randomly selected group of 55 patients who had a serum

sample taken for other serologic studies, from October 1 to November 30, 2019 (before

103 the first cases of COVID-19 were reported).

104 Group 2 (confirmed cases of SARS-CoV-2 infection): 55 patients admitted to the

105 Emergency department between March 1 and April 6, 2020, with suspicion of COVID-

106 19. The PCR was positive for SARS-CoV-2 for all of them.

107 Group 3 (pneumonia of unknown etiology): 63 patients admitted for at least 5 days

between February 9 and April 2, 2020, with a clinical and radiological diagnosis of

109 pneumonia of unknown etiology, in which the PCR for SARS-CoV-2 was negative.

110 They were prospective studied after the validation of the serologic test.

111 Diagnostic methods:

Molecular techniques: Two automatic extractors were used to obtain viral RNA from clinical samples: *MagCore HF16* (RBC bioscience, Taipei, Taiwan) and *Hamilton Microlab Starlet* (Hamilton Company, Bonaduz, Switzerland). RNA amplification was made using two real-time PCR platforms: *VIASURE SARS-CoV-2 Real Time PCR Detection Kit* (Certest Biotech, Zaragoza, Spain) and *Allplex 2019-nCoV assay* (Seegene, Seoul, South Korea). All equipments were used according to the manufacturer's instructions for both the handling and the interpretation of the results.

119 Serology: we applied the AllTest COV-19 IgG / IgM kit (AllTest Biotech, Hangzhou, China) for the serological diagnosis. This test is a gualitative membrane-based 120 immunoassay (immunochromatography) for the detection of IgG and IgM antibodies 121 against SARS-CoV-2 in whole blood, serum or plasma samples. We used 10µL of 122 serum for the performance of the test. For the negative control group (group 1), 123 cryopreserved archive samples were obtained, which were previously defrosted and 124 tempered to room temperature before analysis. The performance of the test and the 125 interpretation of the results were done according to the manufacturer's instructions. 126

127 Clinical data:

Demographic and clinical variables of the study population were obtained from the medical records (age and sex). The time from the onset of symptoms was calculated in groups 2 and 3 from the day of onset of symptoms to the day of the extraction of the sample of serum.

132 Serologic test validation:

The serologic test was evaluated on clinical samples from groups 1 and 2 in order to
assess the sensitivity and specificity of the test:

<u>Group 1 (negative controls)</u>: they were used to evaluate the specificity of the
 serological test. 45 aliquots of cryopreserved sera, corresponding to 45 different
 controls, were recovered from the serum archive.

<u>Group 2: (patients with positive PCR for SARS-CoV-2)</u>: they were used to evaluate the
 sensitivity of the serological test, using PCR as a gold standard. A total of 55 confirmed

cases of SARS-CoV-2 infection were included, and cryopreserved aliquots of serum of
 those patients were used. Those aliquots were previously obtained from samples sent
 to the laboratory to carry out other serologies.

143 Diagnostic performance of the serologic test:

The assessment was performed on patients from <u>group 3 (pneumonia of unknown</u> etiology with negative PCR for SARS-CoV-2). Fresh serum samples from 63 patients were studied.

147 **Statistical analysis**:

We considered a positive result for samples in which IgG, IgM or both of them were detected. Continuous variables are expressed as median and interquartile range (IQR) and categorical variables as proportions. Comparisons between categorical variables were made using the Chi-squared or Fisher's exact two-tailed test and the Mantel-Haenszel test for linear trends. For these comparisons, a *p* value less than or equal to 0.05 was considered significant. Statistical analysis was performed with SPSS v20.0 (IBM Corp., Armonk, NY, USA).

155

156 **Results**

A total of 163 patients were studied. Median age was 62 years (IQR: 51-74); 107 (65.6%) were males. The overall serologic results from the three groups of patients are summarized in **Table 1**.

160 Serologic test validation:

All patients included in group 1 (negative controls) showed negative results for
serological tests. Thus, the serological test presented a specificity of 100%. The overall
sensitivity of the test was 47.3% compared to PCR (Table 1). The sensitivity increased
within the first 2 weeks both for IgM and IgG (p=0.008 and p<0.001, respectively, Table
p, reaching a sensitivity of 73.9% after 14 days from the onset of symptoms. Figure 1
shows the evolution in the positivity rates of the test in group 2: for IgM antibodies, the

positivity increased to a maximum level of 66.7% that was reached approximately 13 to 18 days after the onset of symptoms and then began to decrease until reaching its minimum at 31 to 36 days. IgG positivity rates increased up to 100% at 31 to 36 days after the onset of symptoms.

171

172 Diagnostic performance of the serologic test:

We assessed the serologic test in the group 3 patients (patients with pneumonia of 173 174 unknown etiology and negative PCR). Antibodies against SARS-CoV-2 were detected in 56 out of 63 patients (88.9%), being all of them positive for IgG antibodies. Twenty-175 176 five patients (39.7%) were also positive for IgM antibodies (Table 1). No patient had less than 7 days from onset of symptoms and the positivity rate increased from 7-13 177 days (83.3%) to ≥14 days (91.1%), but this difference was not statistically significant for 178 IgM or IgG (p=1.000 and p=0.397, respectively, Table 3). We observed a similar 179 180 pattern in the evolution of the percentages of positivity for IgM in these patients 181 compared with those belonging to group 2 (Figure 2). However, group 3 patients 182 exhibited a sustained higher positivity rate for IgG from days 13 to 30 after the onset of 183 symptoms.

- 184
- 185
- 186
- 187
- 188
- 189 190
- 191
- 192
- 193
- 194

195

196

197 Table 1. Overall serologic results from the three groups of patients

	Group 1	Group 2	Group 3
Group of patients	(negative	(PCR	(pneumonia of unknown
	controls)	positive)	etiology and negative PCR)
No. patients	45	55	63
Age (years)	55 (34-66)	63 (50-79)	67 (57-74)
Sex (male)	27 (60.0%)	33 (60.0%)	47 (74.0%)
Time from onset of symptoms (days)	Not applicable	11 (7-23)	17 (13-22)
IgG positive	0 (0%)	23 (41.8%)	56 (88.9%)
IgM positive	0 (0%)	12 (21.8%)	25 (39.7%)
Positive result	0 (0%)	26 (47.3%)	56 (88.9%)

¹⁹⁸ **Statistics:** values are expressed as median (interquartile range) and absolute count

199 (percentage). A positive serologic result was defined for samples that resulted positive

200 for either IgM or IgG antibodies.

201

Table 2. Serologic results in group 2 patients (PCR positive) according to the

time from the onset of symptoms

Time from onset of symptoms	< 7 days	7-13 days	≥ 14 days	<i>p</i> -value
No. patients	8 (14.5%)	24 (43.6%)	23 (41.8%)	-
IgG positive	1 (12.5%)	6 (25.0%)	16 (69.6%)	<0.001
IgM positive	0 (0%)	3 (12.5%)	9 (39.1%)	0.008
Positive result	1 (12.5%)	8 (33.3%)	17 (73.9%)	<0.001

204 **Statistics:** values are expressed as absolute count (percentage). A positive serologic

205 result was defined for samples that resulted positive for either IgM or IgG antibodies. P-

- values were calculated by the Mantel-Haenszel test for linear trend. Significant
- 207 differences are shown in **bold**. **Abbreviations**: PCR: polymerase chain reaction.
- 208
- 209 Table 3. Serologic results in group 3 patients (pneumonia of unknown etiology

and negative PCR) according to the time from the onset of symptoms

Time from onset of symptoms	<7 days	7-13 days	≥ 14 days	<i>p</i> -value
No. patients	0 (0%)	18 (28.6%)	45 (71.4%)	-
IgG positive	0 (0%)	15 (83.3%)	41 (91.1%)	0.397
IgM positive	0 (0%)	7 (38.9%)	18 (40.0%)	1.000
Positive result	0 (0%)	15 (83.3%)	41 (91.1%)	0.397

Statistics: values are expressed as absolute count (percentage). A positive serologic result was defined for samples that resulted positive for either IgM or IgG antibodies. P-values were calculated by Fisher's exact two-tailed test. Significant differences are

shown in bold. **Abbreviations:** PCR: polymerase chain reaction.

215

216 **Discussion**

Our study shows that immunochromatographic tests are a reliable tool to diagnose SARS-CoV-2 infection from 14 days of onset of symptoms and are especially useful in hospitalized patients with pneumonia of unknown etiology with 14 or more days from the onset of symptoms and in whom the PCR has been negative.

The current situation of the COVID-19 pandemic requires an urgent and coordinated answer to the inherent problems of the PCR-based diagnosis: on the one hand the low capacity to carry out PCR techniques in some laboratories and also the low sensitivity of PCR test in nasopharyngeal samples, specially from the second week of infection (2,6). This study shows that the *AllTest COVID-19 lgG / lgM* rapid test for the detection 226 of IgG and IgM is very specific (100%) and reaches a sensitivity of 73.9% from day 14 227 of onset of symptoms in patients with previous positive PCR in a nasopharyngeal 228 exudate. There is increasing evidence on the usefulness of serology for diagnosis of SARS-CoV-2 infection, but most of these studies are based on microplate ELISA tests 229 to detect IgA, IgM and IgG antibodies (12,13). These techniques have shown high 230 231 sensitivity and specificity, but they also require special equipment, trained personnel and take several hours to perform. Due to this, there is an increasing interest about the 232 233 usefulness of serologic rapid tests, but there is scarce information about their diagnostic performance. In a recently published study, Liu et al. (10) performed a 234 multicenter evaluation of a serologic rapid test that the authors had developed. In their 235 study, the overall sensitivity was 88.7% and the specificity was 90.6%. However, 236 237 although they achieved a higher sensitivity than that obtained in our study, these authors did not present any data about the time after the onset of symptoms except 238 from 58 out of 525 patients enrolled in the study. Moreover, for this subgroup of 239 patients they only described that the time from the onset of symptoms was 8 to 33 240 241 days. Maybe there was a selection bias in the enrolled patients and most of the recruited cases had long evolution times, possibly leading to these results in sensitivity. 242 243 To the best of our knowledge, our study is the first evaluation of this serologic rapid test 244 which has complete data on the time from the onset of symptoms. As this is a 245 serological test, this kind of information is key in order to interpret properly the 246 sensitivity and specificity results. Additionally, in our experience, the use of these tests 247 allowed diagnosis of COVID-19 infection in 91.1% of a group of 63 patients admitted 248 with a clinical diagnosis of COVID-19 pneumonia and negative PCR in nasopharyngeal 249 exudate. According to our data, the vast majority of patients seroconvert from day 21 250 and this is a key aspect in the management of health care personnel (16) and in 251 population immunity studies related to pandemic control (17).

Our study is subject to some limitations. First, it has been conducted in a single
hospital. Further multicenter studies are necessary to reinforce our findings. Second,

patient selection was made according to the diagnostic needs of our hospital. 254 255 Consequently, group 3 patients were all patients with negative PCR patients with 256 clinical and radiological criteria of pneumonia and because of that, our results could not be generalized to other patients with COVID-19 and other clinical syndromes. 257 Additionally, group 3 patients also presented a longer evolution time than group 2 258 259 patients. This probably explains that the overall positivity rates of the serological test 260 are better than in group 3 (88.9% vs 47.3% in group 2). However, when we focus on 261 patients with 14 or more days from onset of symptoms, the sensitivity and positivity rate increased for groups (91.1% for group 3 and 73.9% for group 2 patients). Because all 262 of these limitations, further studies including all kinds of clinical presentations are 263 needed in order to reinforce our conclusions. 264

The question about the reliability of serologic rapid tests is still under debate (18,19) and more research is needed on this topic. We think that our study may help to point out the usefulness of these rapid tests.

268

269 **Acknowledgements**

We want to thank Carolyn Brimley Norris, from the University of Helsinki Language Services for her help with the preparation of the manuscript.

272

273 **Funding**

- 274 This research received no specific grant from any funding agency in the public,
- commercial, or not-for-profit sectors.

276

277 Compliance with Ethical Standards

- 278 Conflict of interest
- The authors declare that they have no conflicts of interest.
- 280 Informed consent

281 Since the present study is retrospective, informed consent was not required.

282 Ethical approval

- 283 The study was conducted according to the ethical requirements established by the
- 284 Declaration of Helsinki. The Ethics Committee of Hospital Universitario Príncipe de
- Asturias (Madrid) approved the study.
- 286

287 Author contributions

- 288 Study concept and design: FPG, RPT and JCG
- 289 Patients' selection and clinical data acquisition: FPG, RPT, JR, TA, PGH and JCG
- 290 Sample processing: JR, TA and PGH
- 291 Statistical analysis and interpretation of data: FPG and RPT
- 292 Writing of the manuscript: FPG, RPT, JR and JCG
- 293 Critical revision of the manuscript for relevant intellectual content: JR, JCG
- 294 Supervision and visualization: JCG
- All authors read and approved the final manuscript.

296 **References**

- 297 (1) Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of
- 298 Coronavirus Disease 2019 in China. New England Journal of Medicine 2020 February
- 299 **28,;0(0):null**.
- 300 (2) Omer SB, Malani P, Rio Cd. The COVID-19 Pandemic in the US: A Clinical Update.
- 301 JAMA 2020 /04/06.
- 302 (3) Novel Coronavirus (2019-nCoV) situation reports. Available at:
- 303 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
- 304 Accessed Apr 9, 2020.
- 305 (4) Tang Y, Schmitz JE, Persing DH, Stratton CW. The Laboratory Diagnosis of
- 306 COVID-19 Infection: Current Issues and Challenges. J Clin Microbiol 2020.

- 307 (5) Vashist SK. No title. In Vitro Diagnostic Assays for COVID-19: Recent Advances
 308 and Emerging Trends 2020.
- 309 (6) Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al.
- 310 Virological assessment of hospitalized patients with COVID-2019. Nature 2020:1-10.
- 311 (7) To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles
- 312 of viral load in posterior oropharyngeal saliva samples and serum antibody responses
- during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis 2020
 March 23.
- (8) Pan Y, Zhang D, Yang P, Poon LL, Wang Q. Viral load of SARS-CoV-2 in clinical
- samples. The Lancet Infectious Diseases 2020;20(4):411-412.
- 317 (9) Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, et al. Clinical characteristics and
- imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-
- center study in Wenzhou city, Zhejiang, China. Journal of Infection 2020 Apr;80(4):388320 393.
- (10) Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, et al. Evaluation of Nucleocapsid and
- 322 Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2. J Clin
- 323 Microbiol 2020.
- 324 (11) Okba NM, Muller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al.
- 325 SARS-CoV-2 specific antibody responses in COVID-19 patients. medRxiv 2020.
- 326 (12) Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, et al. Profiling Early Humoral
- 327 Response to Diagnose Novel Coronavirus Disease (COVID-19). Clinical Infectious
- 328 Diseases 2020.
- 329 (13) Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to
- 330 SARS-CoV-2 in patients of novel coronavirus disease 2019. 2020.
- (14) Jin Y, Wang M, Zuo Z, Fan C, Ye F, Cai Z, et al. Diagnostic value and dynamic
- variance of serum antibody in coronavirus disease 2019. Int J Infect Dis 2020 April 03.

- 333 (15) Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, et al. Development and Clinical Application
- 334 of A Rapid IgMâ€□ IgG Combined Antibody Test for SARSâ€□ CoVâ€□2 Infection
- 335 Diagnosis. J Med Virol 2020.
- 336 (16) Xiang Y, Jin Y, Wang Y, Zhang Q, Zhang L, Cheung T. Tribute to health workers
- 337 in China: A group of respectable population during the outbreak of the COVID-19. Int J
- Biol Sci 2020;16(10):1739-1740.
- 339 (17) Pang J, Wang MX, Ang IYH, Tan SHX, Lewis RF, Chen JI, et al. Potential rapid
- diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a
- 341 systematic review. Journal of clinical medicine 2020;9(3):623.
- 342 (18) Advice on the use of point-of-care immunodiagnostic tests for COVID-19.
- 343 Available at: https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-
- point-of-care-immunodiagnostic-tests-for-covid-19. Accessed Apr 11, 2020.
- 345 (19) Cassaniti I, Novazzi F, Giardina F, Salinaro F, Sachs M, Perlini S, et al.
- 346 Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of
- 347 COVID-19 in acute patients referring to emergency room department. J Med Virol 2020
- 348 March 30.

349 **Figure captions**

- 350 Figure 1. Temporal evolution of the percentage of positivity for IgM and IgG
- 351 antibodies in group 2 patients (PCR positive)



Figure 2. Temporal evolution of the percentage of positivity for IgM and IgG antibodies in group 3 patients (pneumonia of unknown etiology with negative



